| Sheevani Bhalsod, DO | |
|
701 E County Line Rd Ste 101, Greenwood, IN 46143 | |
| (317) 885-2860 | |
| (317) 885-2869 |
| Full Name | Sheevani Bhalsod |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Experience | 11 Years |
| Location | 701 E County Line Rd Ste 101, Greenwood, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629411236 | NPI | - | NPPES |
| 300019034 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 02005414A (Indiana) | Primary |
| 207R00000X | Internal Medicine | 02005414A (Indiana) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Franciscan Health Indianapolis | Indianapolis, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Francis Medical Group Llc | 7012067697 | 112 |
News Archive
Only half of all patients at high risk of heart disease are given correct targets for lowering their cholesterol levels according to a study of 25,250 patients in Germany published online today (Thursday 11 March) in the European Heart Journal.
Orexigen Therapeutics, Inc. today announced that its 24-week, Phase 2b trial for Empatic(TM) (bupropion SR/zonisamide SR), the Company's second late stage investigational combination drug for the treatment of obesity, met its primary efficacy endpoint by demonstrating statistically significantly greater weight loss for both Empatic doses compared to monotherapies and placebo.
Breast cancer patients are more likely to have joint pain from taking aromatase inhibitors if they have advanced stage cancer, according to a study presented at the American College of Rheumatology's annual meeting, held Nov. 7-11, in Atlanta. The study is one of the first to identify factors that increase the likelihood that a patient will suffer joint pain from AI therapy.
Researchers have pinpointed a mechanism in the brains of mice that could explain why some human mothers become depressed following childbirth. The discovery could lead to improved treatment for postpartum depression.
› Verified 6 days ago
| Entity Name | Indiana Internal Medicine Consultants Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609834357 PECOS PAC ID: 7911899489 Enrollment ID: O20040329000685 |
News Archive
Only half of all patients at high risk of heart disease are given correct targets for lowering their cholesterol levels according to a study of 25,250 patients in Germany published online today (Thursday 11 March) in the European Heart Journal.
Orexigen Therapeutics, Inc. today announced that its 24-week, Phase 2b trial for Empatic(TM) (bupropion SR/zonisamide SR), the Company's second late stage investigational combination drug for the treatment of obesity, met its primary efficacy endpoint by demonstrating statistically significantly greater weight loss for both Empatic doses compared to monotherapies and placebo.
Breast cancer patients are more likely to have joint pain from taking aromatase inhibitors if they have advanced stage cancer, according to a study presented at the American College of Rheumatology's annual meeting, held Nov. 7-11, in Atlanta. The study is one of the first to identify factors that increase the likelihood that a patient will suffer joint pain from AI therapy.
Researchers have pinpointed a mechanism in the brains of mice that could explain why some human mothers become depressed following childbirth. The discovery could lead to improved treatment for postpartum depression.
› Verified 6 days ago
| Entity Name | St Francis Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467693135 PECOS PAC ID: 7012067697 Enrollment ID: O20090603000310 |
News Archive
Only half of all patients at high risk of heart disease are given correct targets for lowering their cholesterol levels according to a study of 25,250 patients in Germany published online today (Thursday 11 March) in the European Heart Journal.
Orexigen Therapeutics, Inc. today announced that its 24-week, Phase 2b trial for Empatic(TM) (bupropion SR/zonisamide SR), the Company's second late stage investigational combination drug for the treatment of obesity, met its primary efficacy endpoint by demonstrating statistically significantly greater weight loss for both Empatic doses compared to monotherapies and placebo.
Breast cancer patients are more likely to have joint pain from taking aromatase inhibitors if they have advanced stage cancer, according to a study presented at the American College of Rheumatology's annual meeting, held Nov. 7-11, in Atlanta. The study is one of the first to identify factors that increase the likelihood that a patient will suffer joint pain from AI therapy.
Researchers have pinpointed a mechanism in the brains of mice that could explain why some human mothers become depressed following childbirth. The discovery could lead to improved treatment for postpartum depression.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sheevani Bhalsod, DO 701 E County Line Rd Ste 101, Greenwood, IN 46143-1070 Ph: (317) 885-2860 | Sheevani Bhalsod, DO 701 E County Line Rd Ste 101, Greenwood, IN 46143 Ph: (317) 885-2860 |
News Archive
Only half of all patients at high risk of heart disease are given correct targets for lowering their cholesterol levels according to a study of 25,250 patients in Germany published online today (Thursday 11 March) in the European Heart Journal.
Orexigen Therapeutics, Inc. today announced that its 24-week, Phase 2b trial for Empatic(TM) (bupropion SR/zonisamide SR), the Company's second late stage investigational combination drug for the treatment of obesity, met its primary efficacy endpoint by demonstrating statistically significantly greater weight loss for both Empatic doses compared to monotherapies and placebo.
Breast cancer patients are more likely to have joint pain from taking aromatase inhibitors if they have advanced stage cancer, according to a study presented at the American College of Rheumatology's annual meeting, held Nov. 7-11, in Atlanta. The study is one of the first to identify factors that increase the likelihood that a patient will suffer joint pain from AI therapy.
Researchers have pinpointed a mechanism in the brains of mice that could explain why some human mothers become depressed following childbirth. The discovery could lead to improved treatment for postpartum depression.
› Verified 6 days ago
Bisher Zuhdi, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 701 E County Line Rd Ste 101, Greenwood, IN 46143 Phone: 317-885-2860 Fax: 317-885-2869 | |
William C Buffie, MD Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 701 E County Line Rd, Suite 101, Greenwood, IN 46143 Phone: 317-885-2860 Fax: 317-885-2869 | |
Brendan K. Sweeny, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 701 E County Line Rd Ste 101, Greenwood, IN 46143 Phone: 317-885-2860 Fax: 317-885-2869 | |
Dr. Gerald L Braverman, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 701 E County Line Rd, Suite 101, Greenwood, IN 46143 Phone: 317-885-2860 | |
Dr. Mohamed H Morad, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 701 E County Line Rd Ste 101, Greenwood, IN 46143 Phone: 317-885-2860 Fax: 317-885-2869 | |
Megan Alyse Mandelbaum, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 701 E County Line Rd Ste 101, Greenwood, IN 46143 Phone: 317-885-2860 Fax: 317-885-2869 |